glp 1 receptor agonist contraindications Incretins: How we got here, where we're at and what is coming next Mapping the effectiveness and risks

Nersessian et al

This means that is not well studied currently, there is no reliable information on the safety and side effects of microdosing GLP-1, and there are no guidelines on how microdosing should occur

95% CI, -0.82% to -0.13%) while maintaining stable kidney function

Notably, DPP-4 inhibitors appear to be safe regarding the risk of fractures, as they tend to decrease this risk, but more clinical trials are needed to explore the effects of DPP-4 inhibitors in other populations beyond T2DM

These drugs are new to us, but theyve been at least a decade in development for diabetes, says Katrina Bicknell, professor of pharmacology and pharmacy education at Reading School of Pharmacy

The most common side effects are mild, including nausea, vomiting, bloating, constipation and diarrhea